GlassScriptPhysician profile
Raymond G Decker
NPI 1972594828
$8,496.87
in general payments reported to CMS, 2019-2025
55 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,150 · 2020: $1,152 · 2021: $980 · 2022: $846 · 2023: $880 · 2024: $1,406 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Long Term Medical Supply Or Device Loan: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.70 |
| Long Term Medical Supply Or Device Loan | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.39 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk As | $1,051.59 | 2019 | |
| Novo Nordisk INC | $1,048.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $704.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $690.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.45 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $357.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $326.96 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Allergan, INC. | $287.45 | 2019-2020 | |
| Amgen INC. | $280.90 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $205.54 | 2020-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $202.51 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $147.78 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $133.47 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $96.54 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.